GCM
EGRX

Gladius Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Gladius Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,421
Closed -$22.4K – 432
2023
Q3 		$22.4K Buy
1,421
+107
+8% +$1.92K ﹤0.01% 335
2023
Q2 		$25.5K Buy
1,314
+262
+25% +$6.22K ﹤0.01% 281
2023
Q1 		$29.8K Sell
1,052
-2
-0.2% -$59 ﹤0.01% 285
2022
Q4 		$30.8K Sell
1,054
-73
-6% -$2.32K ﹤0.01% 300
2022
Q3 		$30K Buy
+1,127
New +$41.4K ﹤0.01% 313

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Gladius Capital Management's EGRX Position: Q4 2023 in Review

Gladius Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 1,421 shares — an estimated $22.4K sold.

Gladius Capital Management first reported a position in EGRX in Q3 2022 and held it in 5 quarters. The position peaked at $30.8K in Q4 2022. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

  • Gladius Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Gladius Capital Management sold 1,421 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $22.4K.
  • Gladius Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 5 quarters.
  • Gladius Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $30.8K in Q4 2022.
  • 104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Gladius Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.